<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846351</url>
  </required_header>
  <id_info>
    <org_study_id>NAC270608</org_study_id>
    <nct_id>NCT01846351</nct_id>
  </id_info>
  <brief_title>Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes</brief_title>
  <official_title>Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New England Retina Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes
      of intravitreal anti-VEGF therapy for eAMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular
      degeneration. Since then we have seen that is not rare to find the coexistence of these
      entities. An ERM may produce intrinsic disorganization of the outer retina leading to
      persistent increased macular thickness and/or edema. This persistent edema may affect the
      effectiveness in the treatment of exudative age-related macular degeneration (eAMD).
      Therefore, this study was designed to evaluate the effect of significant ERM on the visual
      and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the best visual acuity during the follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central macular thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the retinal thickness changes with anti-VEGF treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein angiogram</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of changes in lesion size during follow-up.</description>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Epiretinal Membrane</condition>
  <condition>Age Related Macular Degeneration</condition>
  <eligibility>
    <study_pop>
      <textblock>
        age-related macular degeneration
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Significant epiretinal membrane

          -  Anti-VEGF treatment for age-related macular degeneration

        Exclusion Criteria:

          -  Uveitis

          -  Macular disorders

          -  Diabetic retinopathy

          -  Vascular occlusions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>58 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nauman A Chaudhry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Retina Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter E Liggett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New England Retina Associates</affiliation>
  </overall_official>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New England Retina Associates</investigator_affiliation>
    <investigator_full_name>Peter E. Liggett</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>choroidal neovascularization</keyword>
  <keyword>epiretinal membrane</keyword>
  <keyword>anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

